Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Streptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of Streptococcus pneumoniae. It is an active immunization... It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
- First approval
- Canada, 2005 · United States, 1983 · European Union, 2021
- Also known as
- pneumococcal capsular polysaccharide type 5 vaccine
- Brand names
- Apexxnar
- Pneumovax 23
- Prevenar 13
- Prevnar 20
- Synflorix
- Vaxneuvance
Resolves to
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 5 capsular polysaccharide antigen, and which companies have late-stage candidates in those indications?